Table 1.
Characteristics and treatment outcomes of patients with osteoarticular infections
| Patient | Gender | Age | Device/prosthesis type | Pathogen | Underlying conditions | DAP regimen (mg/kg/day) | Duration of DAP+RIF therapy (days) | Adverse effects | CPK max | Device/prosthesis outcome | DAP+RIF clinical outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | m | 50 | Femur plate | MRSE | Diabetes | 8.0 | 26 | 53 | Device removal | success | |
| 2 | f | 36 | Knee arthopl. | MRSA/MRSEa | Kidney graft | 6.6 | 17 | 9 | Prosth. removal | success | |
| 3 | f | 41 | Femur nail | MRSA/MRSEa | 8.0 | 36 | 272 | Device exchange | success | ||
| 4 | m | 79 | Metatarsal plate | MSSA | 8.8 | 14 | 52 | Device removal | success | ||
| 5 | m | 72 | Bilat. hip arthropl. | MRSA | 8.4 | 122b | Minor fatigue | 108 | Bilat. prosth. exchange | success | |
| 6 | m | 76 | Knee arthopl. | MRSE | Diabetes/statin | 8.3 | 15 | 86 | Partial prosth. exchange | success | |
| 7 | m | 85 | No implant, toe | MRSA | Diabetes/PAD | 8.0 | 15 | Exitus at day 15c | 125 | NR | NE |
| 8 | m | 26 | Ext. Fixator, toe | MRSA | 7.7 | 20 | 79 | Device removal | success | ||
| 9 | m | 51 | Hip arthopl. | MSSA | AD /Steroids | 8.9 | 42 | 266 | Prosth. retention | success | |
| 10 | m | 61 | Knee arthopl. | MRSE | 8.8 | 70 | Minor myalgia | 90 | Prosth. retention | success | |
| 11 | f | 51 | No implant, lumbar | MSSA | 7.2 | 42 | Ileus, RIF-assoc. rash | 8 | NR | success | |
| 12 | f | 52 | Ankle plate | MSSA | Hepatitis C | 8.5 | 10 | 135 | Device retention | success | |
| 13 | f | 75 | Hip arthopl. | MRSA | 7.7 | 42 | 5 | Prosth. retention | success | ||
| 14 | m | 72 | Kneecap cerclage | S. mitis | 8.0 | 21 | 103 | Device exchange | success | ||
| 15 | m | 66 | Tibia nail | MRSA | Diabet./statin/PAD | 8.7 | 21 | 305 | Vasc. Prosth. Removald | success | |
| 16 | m | 71 | No implant, toe | MSSA | Diabetes | 8.9 | 14 | 59 | NR |
AD autoimmune disease, PAD peripheral arterial disease, NR non relevant, NE not evaluable, DA daptomycin, RIF rifampicin
aCo-infected with MRSA and MRSE
bPatient received 900 mg/day rifampicin
cPatient died from endocarditis and sepsis
dPatient had limb amputation